Cargando…
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
There is no standard therapy for refractory acute myeloid leukemia (AML), but several salvage therapies are available (National Comprehensive Cancer Network [NCCN], 2018). Recently, there have been major developments in the treatment of AML focusing on the development of targeted and novel therapies...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779565/ https://www.ncbi.nlm.nih.gov/pubmed/33457062 http://dx.doi.org/10.6004/jadpro.2019.10.5.7 |